Navigation Links
Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award
Date:7/14/2009

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, has received the 2009 Silver Medical Design Excellence Award in the general hospital devices and therapeutic products category for the Masimo Rad-87 Pulse CO-Oximeter. The award recognizes Rad-87's excellence in medical technology engineering and design as an intuitive bedside patient monitor that helps improve clinical efficiency and keep patients safe when a clinician can't be at the bedside.

The Masimo Rad-87 features the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET((R)) Pulse CO-Oximetry for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI (fluid responsiveness), perfusion index, and measure through motion pulse oximetry with upgradability to acoustic respiration rate monitoring. Its built-in 802.11a/b/g radio allows wireless communication with the Masimo Patient SafetyNet(TM) remote monitoring and clinician notification system to provide patients with an enhanced level of safety on general care floors. Designed for ease-of-use, the Rad-87 allows the features clinicians need most often to be accessed with a single touch. And, as the first Masimo Rainbow SET device with a bright white LED-based display, its high contrast visual display allows measurements to be clearly seen from across the room, while an innovative new device profile feature lets clinical settings be customized and color-coded for a particular care area.

Masimo Founder and CEO, Joe E. Kiani, stated, "It is an honor to receive our third Medical Design Excellence Award for product design and engineering innovations that improve healthcare delivery and advance medical practices. We received the Gold Medical Design Excellence Award in 2006 for the Masimo Rad-57 Pulse CO-Oximeter and in 2001 for the Masimo Radical Signal Extraction pulse oximeter."

The Medical Design Excellence Awards (MDEA) competition is the only awards program that exclusively recognizes advances in the design of medical products and the achievements of medical device manufacturers responsible for the groundbreaking innovations that are changing the face of healthcare. 2009 MDEA winners were announced and honored at the June 10th ceremony during the Medical Design & Manufacturing (MD&M) East Conference and Exposition in New York. For more information about the Medical Design Excellence Awards--including details about the winning products--visit www.MDEAwards.com.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO((R))), methemoglobin (SpMet((R))), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that the features, function and design of the Masimo Rad-87 Pulse CO-Oximeter will enable clinicians to detect and treat life-threatening conditions earlier, improve patient outcomes, increase clinical efficiency gains, and reduce the cost of care for patients, risks related to our belief that Masimo Rainbow SET Pulse CO-Oximetry technology will provide a sufficient level of sensitivity and specificity to facilitate the noninvasive, continuous measurement of multiple blood constituents, fluid assessment and physiological parameters, risks related to our assumption that the combination of Masimo Rad-87 and Masimo Patient SafetyNet will help clinicians keep patients safe on general care floors, as well as other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission ("SEC") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission ("SEC") on May 6, 2009, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Contact:
    Dana Banks
    Masimo Corporation
    949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Masimo Debuts New Rad-8(R) Pulse Oximeter to Largest Gathering of Sleep Specialists From Around the World at SLEEP 2009
2. Leading University Hospital Completes System-Wide Conversion to Masimo SET(R) Pulse Oximetry
3. FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List
4. Capgemini Releases New Study on Financial Impact of Masimo Noninvasive and Continuous Hemoglobin (SpHb(TM))
5. New Clinical Study Finds Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Accurate in the Noninvasive Monitoring of Fluid Status During Surgery
6. Masimo to Present at the Cowen and Company 29th Annual Healthcare Conference
7. Masimo Reports Fourth Quarter and Full Year 2008 Financial Results
8. Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members
9. Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
10. Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009
11. Masimo Files Patent Infringement Suit Against Philips
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: